# EDGAR Filing Document

**Accession Number:** 0001601936
**File Stem:** 0001213900-25-053451
**Filing Date:** 2025-6
**Character Count:** 4864
**Document Hash:** d97ae283cbc92f1208c7b6360adcd8d3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-053451.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001213900-25-053451

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250611

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Altamira Therapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001601936
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36582
- **FILM NUMBER:** 251040166

**BUSINESS ADDRESS:**
- **STREET 1:** CLARENDON HOUSE
- **STREET 2:** 2 CHURCH STREET
- **CITY:** HAMILTON HM 11
- **STATE:** D0
- **ZIP:** 00000
- **BUSINESS PHONE:** 41 (0) 41 729 71 94

**MAIL ADDRESS:**
- **STREET 1:** CLARENDON HOUSE
- **STREET 2:** 2 CHURCH STREET
- **CITY:** HAMILTON HM 11
- **STATE:** D0
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Auris Medical Holding Ltd.
- **DATE OF NAME CHANGE:** 20190318

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Auris Medical Holding AG
- **DATE OF NAME CHANGE:** 20190314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Auris Medical Holding Ltd.
- **DATE OF NAME CHANGE:** 20190312

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June 2025

**Commission File Number: 001-36582**

**Altamira Therapeutics Ltd.**

**(Exact name of registrant as specified in its charter)**

**Clarendon House, 2 Church Street**

**Hamilton HM 11, Bermuda**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

**Annual General Meeting Results**

On June 11, 2025, Altamira Therapeutics Ltd. (the "Company") held its Annual General Meeting of Shareholders. Based on the presence in person or by proxy of holders of the Company's outstanding ordinary shares constituting a quorum, each of the agenda items submitted to a vote of the shareholders was duly adopted by the requisite majority in accordance with the Company's Bye-Laws:

**Agenda Item 1: Election of the Members of the Board of Directors**

The Company's shareholders elected Messrs. Thomas Meyer, Alain Munoz, Mats Peter Blom and Dominik Lysek, as members of the Board of Directors, each for a term of one year ending upon completion of the 2026 Annual General Meeting (or until their respective successors are elected).

**Agenda Item 2: Appointment of Auditors**

The Company's shareholders re-elected BDO AG, Zurich, as auditors of Altamira Therapeutics Ltd. for the 2025 financial year.

**INCORPORATION BY REFERENCE**

This Report on Form 6-K, shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Numbers [333-249347](https://www.sec.gov/Archives/edgar/data/1601936/000121390020030341/ea127798-f3_aurismedical.htm), [333-264298](https://www.sec.gov/Archives/edgar/data/1601936/000121390022019867/ea158004-f3_altamiratherap.htm), [333-267584](https://www.sec.gov/Archives/edgar/data/1601936/000121390022058423/ea166039-f3_altamiratherap.htm), [333-272338](https://www.sec.gov/Archives/edgar/data/1601936/000121390023045067/ea179110-f3_altamiratherap.htm) and [333-276427](https://www.sec.gov/Archives/edgar/data/1601936/000121390024001961/ea190535-f3_altamira.htm)) and Form S-8 (Registration Numbers [333-232735](https://www.sec.gov/Archives/edgar/data/1601936/000121390019013206/fs82019_aurismedical.htm), [333-252141](https://www.sec.gov/Archives/edgar/data/1601936/000121390021002526/ea133358-s8_aurismedical.htm), [333-278595](https://www.sec.gov/Archives/edgar/data/1601936/000121390024031738/ea0203561-s8_altamira.htm) and [333-286392](https://www.sec.gov/Archives/edgar/data/1601936/000121390025029036/ea0236526-s8_altamira.htm)) of Altamira Therapeutics Ltd. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Altamira Therapeutics Ltd.** | **Altamira Therapeutics Ltd.** | **Altamira Therapeutics Ltd.** |
| Date: June 11, 2025 | By: | /s/ Thomas Meyer | /s/ Thomas Meyer |
|  |  | Name: | Thomas Meyer |
|  |  | Title: | Chief Executive Officer |

---